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Abstract: Convection-enhanced delivery (CED) is a novel approach for delivering drugs directly 
into brain tumors by intracranial infusion, enabling the distribution of high drug concentrations 
over large tissue volumes. This study was designed to present a method for binding methotrexate 
(MTX) to unique crystalline, highly ordered and superparamagnetic maghemite nanoparticles 
via human serum albumin (HSA) coating, optimized for CED treatments of gliomas. Naked 
nanoparticles and HSA- or polyethylene glycol (PEG)-coated nanoparticles with/without 
MTX were studied. In vitro results showed no toxicity and a similar cell-kill efficacy of the 
MTX-loaded particles via HSA coating to that of free MTX, while MTX-loaded particles via 
PEG coating showed low efficacy. In vivo, the PEG-coated nanoparticles provided the largest 
distributions in normal rat brain and long clearance times, but due to their low efficacy in vitro, 
were not considered optimal. The naked nanoparticles provided the smallest distributions and 
shortest clearance times. The HSA-coated nanoparticles (with/without MTX) provided good 
distributions and long clearance times (nearly 50% of the distribution volume remained in the 
brain 3 weeks post treatment). No MTX-related toxicity was noted. These results suggest that 
the formulation in which HSA was bound to our nanoparticles via a unique precipitation method, 
and MTX was bound covalently to the HSA, could enable efficient and stable drug loading with 
no apparent toxicity. The cell-kill efficacy of the bound MTX remained similar to that of free 
MTX, and the nanoparticles presented efficient distribution volumes and slow clearance times 
in vivo, suggesting that these particles are optimal for CED.
Keywords: convection-enhanced delivery, nanoparticles, methotrexate, magnetic   resonance 
imaging, rat brain
Introduction
Malignant primary brain tumors, especially the highly malignant recurrent glio-
blastoma multiforme (GBM), are fatal within months of diagnosis. Chemotherapy 
confers no significant survival advantage, in part due to the poor penetration of most 
chemotherapeutic drugs across the blood–brain barrier (BBB). Convection-enhanced 
delivery (CED) is a novel approach to deliver drugs directly into brain tumors. It is 
based on delivering a continuous infusion of drugs via intracranial catheters, enabling 
the convective distribution of high drug concentrations over large volumes of tissue 
while avoiding systemic toxicity.1–4
Efficient CED formation depends on various physical/physiological parameters.5,6 
Previous CED-based clinical trials showed a significant diversity in the extent of con-
vection among patients and drugs. We have previously shown that CED formation/
extent may be significantly improved by increasing infusate viscosities.7 Efficient CED International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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is currently limited to small molecules (,200 kDa). We 
have recently demonstrated the application of our increased 
efficacy methodologies to enable efficient CED of maghemite 
nanoparticles in a normal rat brain model.8 The authors 
have also established the validity of using magnetic reso-
nance imaging (MRI) for depicting the distribution of the 
convected maghemite nanoparticles in the brain. This study 
also demonstrated the long clearance time of the maghemite 
nanoparticles from the brain (weeks to months) with no 
evidence of toxicity.
Methotrexate (MTX) is a folic acid analog used as a 
  chemotherapeutic agent. As folate receptors are over expressed 
on the cell membranes of many types of cancer cells, MTX 
is one of the most widely used drugs for the treatment of 
many forms of cancer, including tumors of the brain, breast, 
ovaries, and several leukemias. However, MTX is limited by 
its low solubility, dose-related toxicity, lack of   selectivity, 
rapid   diffusion throughout the body, short half-life in the 
bloodstream, and drug resistance by target cells.9,10 Recent 
literature indicates increasing interest in binding MTX to 
nanoparticles to alter its pharmacokinetic behavior, enhance 
tumor targeting, reduce toxicity, and overcome drug-  resistance 
mechanisms.11–14 In this study we used the combination of 
nanoparticles with CED, thus avoiding the main limitation 
introduced by systemic administration.
Magnetic nanoparticles are considered to be spherical 
particles with magnetic properties in sizes ranging from a 
few nm to approximately 100 nm. These particles, because of 
their spherical shape, large surface area and magnetic prop-
erties, may have a wide range of potential applications.15–21 
Magnetic nanoparticles that have been approved by the FDA 
are Feridex and Combidex, used as MRI contrast agents. 
These are prepared by reacting ferrous and ferric salts in the 
presence of appropriate surfactants (or polymers) in an aque-
ous phase under severe basic conditions, producing a broad 
size distribution (considered a potential source of toxicity). 
Particles prepared this way often suffer from lack of stability 
due to agglomeration, and the technology to covalently bind 
bioactive reagents (ie, proteins) to their surface, particularly 
to the smallest available particles, is still obscure. Further-
more, since these nanoparticles are prepared under basic 
conditions, the encapsulation of sensitive bioactive reagents, 
eg, proteins, within the nanoparticles for drug delivery and 
controlled-release applications is not efficient due to dena-
turation of the proteins. Other highly investigated super-
paramagnetic nanoparticles, MION (monocrystalline iron 
oxide nanocompounds and AMI-25 (Advanced Magnetics, 
Inc, Cambridge, MA),22,23 also prepared similarly by the   
interaction of ferrous and ferric salts in an aqueous phase 
under basic conditions, possess similar limitations and are 
not yet suitable for clinical use.
The authors have recently prepared and characterized 
new uniform magnetic maghemite (γ-Fe2O3) nanoparticles,23 
formed via controlled nucleation and then the growth of thin 
films of maghemite onto gelatin/iron oxide nuclei. These 
particles can be prepared in sizes of 15–80 nm. They are 
biodegradable, nontoxic and have a narrow size distribution. 
Their preparation is simple and can be performed close to 
physiological pH, with a yield of almost 100%. These nano-
particles are also superparamagnetic, enabling real-time 
imaging with MRI. Using these nanoparticles, biocompatible, 
stabilized particles containing various functional groups are 
prepared by coating with a variety of polymers including 
proteins, polysaccharides such as dextran, and polyethylene 
glycols. The functional groups of these coatings can then be 
used for the covalent binding of bioactive reagents such as 
drugs, proteins, antibodies and enzymes, to the surface of 
these maghemite nanoparticles.24–26
Since maghemite nanoparticles have been shown to 
  provide increased uptake in cancer cells versus normal cells,27 
and since human serum albumin (HSA) and polyethylene 
glycol (PEG) have been shown to increase the intake of MTX 
into cancer cells,12,28,29 this study focuses on developing a 
methodology to bind MTX, a well-proven anti-tumor agent 
active in GBM, via HSA to the magnetic nanoparticles. The 
uptake of the drug-loaded particles and the efficacy of the 
drug-loaded particles versus the efficacy of the free drug 
were studied in vitro, followed by in vivo CED experiments 
to study the efficacy of distribution and clearance patterns 
of the nanoparticles in the brain.
The efficient CED of nanoparticles may enable the use 
of drugs and/or drug carriers that until now were considered 
inappropriate for convection treatment. Nanoparticles as 
drug carriers may enable the real-time depiction of particle 
distribution in the tissue, provide slow drug release, enable 
the delivery of larger therapeutic agents, and allow targeted 
drug delivery.30–32
Materials and methods
In vitro and in vivo experimental outline
To obtain methotrexate-loaded maghemite nanoparticles, 
which are both effective in treating cancer cells, yet nontoxic 
to a normal brain, and taking into account the fact that animal 
brain tumor models do not simulate human tumors as regards 
consistency (and therefore are suboptimal for convection-
based studies), the experiments were performed separately International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in vitro and in vivo. The in vitro experiments were designed 
to establish the anti-tumor efficacy of the drug-loaded par-
ticles and confirm that the vehicles (the nonloaded particles) 
were nontoxic. In these experiments, 9L gliosarcoma cells 
were incubated with the drug-loaded particles and controls 
for 48 hours. Following the incubation period, the cells were 
counted and the cell kill of each treatment was calculated. 
Once the drug-loaded particles were shown to be effective 
and the nonloaded particles were shown to be nontoxic, they 
were subjected to further studies in vivo.
An additional in vitro experiment was designed to deter-
mine the efficacy of the penetration of the nanoparticles 
into the cells, using MRI. In this experiment the cells were 
incubated for 24 hours with the nanoparticles. The cells 
were then rinsed and a pellet was prepared. Pellet vials were 
placed in the MRI together with calibration vials containing 
free nanoparticles at different concentrations. The γ-Fe2O3 
concentration of the pellets was determined by comparing 
the contrast of the pellet vials and the calibration vials, as 
depicted in the magnetic resonance (MR) images.
The in vivo experiments were designed to study the 
  distribution efficacy of the different particles in normal rat 
brains, to assess the clearance time from the brain, and to 
assess the toxicity to a normal brain. The tested solutions 
were infused into the rats’ brains through an intracranial 
catheter. The rats were scanned by MRI immediately after 
the infusion and then once a week, and thereafter for a period 
of 3 weeks. In addition, the rats were weighed once a week. 
The distribution efficacy was determined from the volumes 
of distribution, calculated from the MR images acquired 
immediately post treatment. The clearance time from the 
brain was determined by following the changes in the volume 
of distribution as a function of time, throughout the 3-week 
follow-up. Toxicity was determined by survival and weight 
gain throughout the 3-week follow-up.
Materials
Methotrexate (MTX), glycine, divinyl sulfone (DVS), 
  triethylamine (TEA), dimethyl sulfoxide (DMSO), FeCl2, 
NaNO3, potassium persulfate, 1-ethyl-3-(3-dimethylamin-
opropyl) carbodiimide (EDC), N-hydroxysulfosuccinimide 
(sulfo NHS), NaOH, gelatin (from porcine skin), human 
serum albumin (HSA), polyethylene glycol (PEG, MW 
400), PEG (MW 400) methacrylate (PEGMA), PEG dime-
thacrylate (PEGDMA) and amino terminated PEGMA 
(NH2PEGMA) were all purchased from Sigma (Rehovot, 
Israel). Salts for buffers were purchased from Bio-Lab Ltd 
(Jerusalem, Israel). Formaldehyde was purchased from 
Gadot Biochemical Industries, Ltd (Haifa Bay, Israel). 
Water was purified by passing deionized water through an 
Elgastat Spectrum reverse osmosis system (Elga Ltd, High 
Wycombe, UK).
Synthesis of the maghemite  
nanoparticles (γ-Fe2O3)
Maghemite nanoparticles (γ-Fe2O3) of narrow size   distribution 
were prepared by nucleation followed by the controlled growth 
of iron oxide thin films onto the gelatin/iron oxide nuclei, as 
previously described.29 Briefly, γ-Fe2O3 of 19.8 ± 4.7 nm dry 
diameter were prepared by adding a FeCl2 aqueous solution 
(10 mmol/5 mL in 0.1 N HCl) to 80 mL of an aqueous solution 
containing 240 mg of porcine gelatin, followed by the addition of 
a NaNO3 solution (7 mmol/5 mL in H2O). After a reaction time 
of 10 minutes, a NaOH   aqueous solution (1 N) was added until a 
pH of 9.5 was obtained. This procedure was repeated four more 
times. During the entire procedure, the aqueous   suspension was 
agitated at 60°C and kept in an inert   environment. The formed 
γ-Fe2O3 nanoparticles were then washed from excess reagents 
with H2O using magnetic columns.
Physical adsorption of hSA  
onto the maghemite nanoparticles 
(γ-Fe2O3∼hSA) by precipitation
Ten milligrams of HSA was added to 50 mL of the γ-Fe2O3 
nanoparticles dispersed in water (2 mg/mL). The reaction 
mixture was then shaken at pH 9.5 and 60°C for 24 hours, 
and then cooled gradually to room temperature. The obtained 
γ-Fe2O3∼HSA nanoparticles (∼ is a symbol for the HSA 
physical coating obtained by precipitation) were then washed 
from excess HSA with phosphate-buffered saline by mag-
netic columns.
Polymerization of polyethylene glycol  
acrylate derivatives on the surface of the  
maghemite nanoparticles (γ-Fe2O3∼Peg)
Polymerization of PEGMA monomers on the surface of the 
maghemite nanoparticles was accomplished by   mixing 25 mL 
of the maghemite nanoparticles dispersed in a bicarbonate 
buffer (0.1 M, pH 8.3, 4 mg/mL) with 0.35 mL of PEGMA, 
0.05 mL of PEG dimethacrylate (PEGDMA), 0.1 mL of 
NH2PEGMA, and 24 mg of potassium persulfate dissolved 
in 25 mL of a bicarbonate buffer (0.1 M, pH 8.3). For the 
  polymerization process, the above mixture was shaken at 73°C 
for 4 hours. The formed γ-Fe2O3∼PEG-NH2 particles were then 
washed from excess monomers by magnetic columns.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Physical conjugation of methotrexate 
to the hSA-coated nanoparticles 
(γ-Fe2O3∼hSA∼MTX)
MTX was physically conjugated to the HSA coated 
  nanoparticles, γ-Fe2O3∼HSA, by adding 1 mg of MTX 
dissolved in 1 mL of DMSO to 20 mL of the nanoparticle 
dispersion in PBS (1 mg/mL). The reaction mixture was 
then shaken at room temperature for 18 hours. The obtained 
γ-Fe2O3∼HSA∼MTX nanoparticles were then washed from 
excess MTX with PBS (0.1 M, pH 7.3) by magnetic columns. 
Higher concentrations of MTX were obtained by increasing 
the initial MTX concentration.
Covalent binding of MTX  
to the hSA-coated and Peg-coated  
nanoparticles (γ-Fe2O3∼hSA-MTX,  
γ-Fe2O3∼Peg-MTX)
MTX was covalently conjugated to the HSA-coated 
  nanoparticles, γ-Fe2O  ∼HSA. In a typical experiment, 5 mg of 
MTX dissolved in 2.5 mL of DMSO was added to 2.5 mg of 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 
5 mg sulfo-NHS dissolved in 2.5 mL of water. The mixture 
was then shaken at room temperature for 15 minutes. Twenty 
milliliters of the HSA-coated nanoparticles (γ-Fe2O3∼HSA, 
1 mg/mL) were then added and the mixture was shaken at 
room temperature for 1 hour, after which the nanoparticles 
were washed from excess reagents by magnetic columns. 
In a similar way MTX was conjugated to the terminal NH2 
groups of the γ-Fe2O3∼PEG-NH2 nanoparticles. Higher con-
centrations of MTX were obtained by increasing the initial 
MTX concentration.
Determination of the bound hSA  
concentration
The concentration of HSA bound to the γ-Fe2O3 nanoparticles 
was determined by measuring the unbound proteins using 
the Bradford assay33,34 and subtracting it from the initial 
concentration. The reported values are an average of at least 
three measurements of each sample. The binding yield was 
calculated by multiplying the ratio of the concentration of 
the bound MTX to the initial concentration by 100.
Determination of the bound MTX 
concentration
The concentration of MTX bound to the γ-Fe2O3   nanoparticles 
was indirectly determined by measuring the absorbance of the 
unbound drug at 303 nm. The binding yield was   calculated 
by multiplying the ratio of the concentration of the bound 
MTX to the initial concentration by 100.
Cell culture procedures
9L gliosarcoma cells, which overexpress the folate   receptor, 
were maintained at 37°C and 5% CO2 in Dulbecco’s   Modified 
Eagle’s Medium (DMEM) (Biological Industries, Kibbutz 
Beit Haemek, Israel) enriched with 10% FCS and 1% peni-
cillin/streptomycin and subcultured twice a week. The cells 
were plated at a density of 6 × 104 per well in 24 well plates 
for the cell-kill experiments and at 1 × 106 per 10 cm plates 
for the in vitro MRI experiments. The cells were incubated 
for 24 hours and then treated with the indicated concentra-
tion of the therapeutic agents or with the vehicles. Treatment 
duration was 24 hours for the in vitro MRI   experiments and 
48 hours for the cell-kill experiments.
In vitro cell-kill experiments
9L cells were treated with the therapeutic agent or with the 
vehicle for 48 hours. The concentration of the particles was 
0.2 mg/mL and the concentration of the bound MTX was 
1 µg/mL. The effect of the treatment on cell growth was deter-
mined by direct counting of the cells collected from each well 
using a trypan blue assay. To calculate the average   percentage 
of viable cells, the number of cells counted for each treatment 
was divided by the number of cells in the control group. The 
experiment was performed in quadruplicate.
In vitro MrI experiments
In order to determine whether the nanoparticles penetrated 
the 9L cells efficiently, 9L cells were incubated with γ-Fe2O3 
nanoparticles and γ-Fe2O3∼HSA nanoparticles (0.2 mg/mL) 
for 24 hours. A pellet was prepared from each of the two 
particle types. The pellet was rinsed twice with PBS and 
placed in 1.5 mL vials. Calibration vials were prepared with 
free γ-Fe2O3 nanoparticles at concentrations ranging between 
0.06–6.0 mg/mL. The two-pellet vials were placed in the MRI 
coil together with the calibration vials to assess the γ-Fe2O3 
concentration in the pellets.
In vivo CeD experiments
The study was performed in accordance with the guidelines 
of The Animal Care and Use Committee of Sheba Medical 
Center, which is recognized by the Israeli authorities for 
animal experimentation. The CED of nanoparticles was 
performed into the striatum of normal Sprague-Dawley male 
rats (280–320 g) under full anesthesia at a rate of 4 µL/min 
over 15 minutes. Immediately after the infusion the rats International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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were scanned by gradient-echo MRI for assessment of the 
nanoparticle distribution, and by T2-weighted MRI for 
the depiction of procedure-related toxicity. The rats were 
scanned and weighed once a week for an additional period 
of 3 weeks for assessment of the toxicity and clearance time 
of the nanoparticles.
Thirteen rats were treated with CED of γ-Fe2O3∼PEG, 
11 rats with γ-Fe2O3∼HSA, 14 rats with γ-Fe2O3∼HSA-MTX, 
and 11 rats with γ-Fe2O3.
CeD procedure
Under full anesthesia, a midline scalp incision was made 
to identify the bregma. A 1-mm burr hole was made in the 
right region of the skull, 2 mm lateral and 3 mm posterior 
to the bregma. A 30-gauge needle attached to a 1000 μL 
syringe (Gastight; Hamilton Company, Reno, NV) was placed 
  stereotactically 5.5 mm deep in the rat striatum. The infusion 
was performed using a BASi syringe pump (Bioanalytical 
Systems Inc, West Lafayette, IN) at a rate of 4 µL/min for 
15 minutes.
Imaging protocol
Gradient-echo and T2-weighted MR images were acquired 
using a 1.5T GE MRI system and the standard phased-array 
GE head-coil. Gradient-echo MRI were acquired with a 
512 × 512 matrix, 16 × 12 cm2 field of view, repetition time 
of 425 ms, echo time of 15 ms, a flip angle of 15° and 2 mm 
slices with no gap. T2-weighted fast spin echo MRI were 
acquired with a 512 × 512 matrix, 16 × 12 cm2 field of view, 
repetition time of 5,500 ms, echo time of 80.2 ms, and 2 mm 
slices with no gap.
Calculation of maghemite nanoparticle  
distribution area
The area (in mm2) of the infusate distribution was calculated 
from the gradient-echo MR images. Regions of interest (ROIs) 
were defined over the entire signal void region in each slice 
(excluding the ventricles). The number of pixels in the ROIs 
were counted and multiplied by the volume of a single pixel. 
Data are presented as mean ± standard   deviation (SD).
Results
MRI for assessment of γ-Fe2O3 and γ-Fe2O3∼HSA penetration 
into the cells: Pellets prepared from 9L cells incubated with 
γ-Fe2O3 and γ-Fe2O3∼HSA nanoparticles were placed in the 
MRI together with calibration vials containing free nanopar-
ticles at concentrations ranging between 0.06–6.0 mg/mL. 
The MR images (Figure 1) showed that both pellets consisted 
of 0.2 ± 0.075 mg/mL γ-Fe2O3.
In vitro 9L cell-kill experiments
9L cells were treated with γ-Fe2O3∼PEG, γ-Fe2O3∼PEG-
MTX, γ-Fe2O3∼HSA and γ-Fe2O3∼HSA-MTX for 48 hours. 
The γ-Fe2O3∼HSA particles showed no toxicity: 2% ± 2% cell 
kill. The γ-Fe2O3∼HSA-MTX showed a similar efficacy to that 
of free MTX: 63% ± 6% and 77% ± 4% respectively. The 
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Figure 1 gradient-echo magnetic resonance images of pellets prepared from 9L cells incubated with 0.2 mg/mL γ-Fe2O3 and γ-Fe2O3∼hSA and calibration vials containing free 
maghemite nanoparticles at concentrations ranging from 0.06 mg/mL to 6.0 mg/mL. The magnetic resonance imaging shows that both pellets consisted of 0.2 ± 0.075 mg/mL γ-Fe2O3.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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γ-Fe2O3∼PEG were marginal in means of toxicity: 6% ± 4%, 
but the efficacy of the γ-Fe2O3∼PEG-MTX was relatively low 
with a wide range of variability: 40% ± 19%.
In vivo experiments
The highest average distribution volume, as   calculated 
from  the  MR  images  acquired  immediately  post 
  treatment, was obtained by the CED of γ-Fe2O3∼PEG: 
118.1 ± 11.3 mm3 (Figure 2). However, this volume was 
not significantly higher than the volume of distribution of 
the γ-Fe2O3∼HSA:103.6 ± 13.1 mm3. The distribution of 
the γ-Fe2O3∼HSA-MTX   nanoparticles was lower than that 
of the particles without the drug: 80.2 ± 6.9 mm3. This dif-
ference was not significant statistically, although the differ-
ence between the γ-Fe2O3∼PEG and the γ-Fe2O3∼HSA-MTX 
nanoparticles was significant (P , 0.007, unpaired t test), 
suggesting that the drug may somewhat impair the efficacy of 
convection. The naked particles, γ-Fe2O3, showed the lowest 
volumes of distributions: 36.1 ± 4.4 mm3. These volumes were 
significantly lower than all the coated   particles (P , 0.0002 
versus γ-Fe2O3∼PEG, P , 0.0008 versus γ-Fe2O3∼HSA and 
P , 0.0003 versus γ-Fe2O3∼HSA-MTX, Mann–Whitney 
test.35). Examples of the MRI-depicted distributions as a 
function of time are shown in Figure 3.
The rats were weighed once a week for the duration of 
the study and the average weight gain was calculated for each 
group at each time point (Figure 4). All rats gained 16%–17% 
of their body weight by the end of the 3-week follow-up period: 
the γ-Fe2O3∼PEG group gained 16% ± 2%, the γ-Fe2O3∼HSA 
group 18% ± 1%, the γ-Fe2O3∼HSA-MTX group 17% ± 1%, 
and the γ-Fe2O3 group 18% ± 1%. There were no significant 
differences among any of the groups, suggesting no apparent 
toxicity.
Twelve rats died of the anesthesia administered for the 
MRI follow-ups. This high rate of mortality is attributed to 
the repeated anesthesia and not to treatment-related toxicity, 
since all deaths occurred within a few hours of anesthesia 
administration (the rats never woke up afterwards). In the 
γ-Fe2O3∼PEG group, one rat died following the 2-week 
follow-up MRI and two rats died following the 3-week 
MRI. In the γ-Fe2O3∼HSA group, one rat died following the 
1-week follow-up MRI, one rat died following the 2-week 
follow-up and one rat died following the 3-week follow-up. 
In the γ-Fe2O3∼HSA-MTX group, one rat died following 
the 2-week follow-up MRI and two rats died following the 
3-week MRI follow-up. In the γ-Fe2O3 group, 1 rat died after 
the 1-week MRI follow-up and two rats died following the 
3-week MRI follow-up. Since there was no difference in 
mortality among the three groups, and all deaths occurred 
soon after administration of the anesthesia, it was concluded 
that mortality was not treatment related.
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Figure  2  Nanoparticle  distribution  volumes  in  rat  brain  as  a  function  of  time 
post-CeD treatment for the 4 treatment groups. The distribution volumes were 
calculated  from  gradient-echo  magnetic  resonance  images  acquired  immediately 
post treatment and 5, 12, and 19 days thereafter.
Abbreviation: CeD, convection-enhanced delivery; Peg, polyethylene glycol; hSA, 
human serum albumin; MTX, methotrexate.
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Figure 3 gradient-echo magnetic resonance images of nanoparticle distributions as 
a function of time for a rat treated with γ-Fe2O3~hSA-MTX (A) and a rat treated 
with γ-Fe2O3 (B).
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Discussion
CED is a novel approach to directly deliver drugs into brain 
tumors, producing a high concentration of the drug over 
large volumes within the tumor, while avoiding systemic 
toxicity. However, initial clinical experience indicates that 
the main pitfalls of this methodology are the difficulties 
in forming efficient convection, limited monitoring, and 
nonspecific toxicity. Efficient CED is currently limited to 
small molecules. The present study was aimed at applying 
our increased efficacy and imaging methodologies to enable 
the efficient CED of drug-loaded nanoparticles, leading the 
way for therapeutic agents and/or drug carriers that until 
now were considered inappropriate for convection treatment. 
Nanoparticles as carriers may enable real-time depiction of 
the drug distribution, slow drug release, delivery of larger 
therapeutic agents, and allow targeted drug delivery.
The superparamagnetic maghemite nanoparticles we 
used are optimal for clinical application due to the   uniform 
  nanoparticle population of very narrow size   distribution. 
In order to optimize for the increased efficacy of the 
  nanoparticle distribution in the brain, and in order to obtain 
efficient binding of the MTX without compromising the 
efficacy of the drug, coating with both PEG and HSA was 
studied.
The particles not containing drug – γ-Fe2O3∼PEG, 
γ-Fe2O3∼HSA and the naked γ-Fe2O3 particles showed no 
significant toxicity in vitro, implying that these particles may 
be used as drug carriers. The particles in which MTX was 
bound via PEG, γ-Fe2O3∼PEG-MTX, showed a low cell-kill 
efficiency with a wide range of variability, suggesting poor 
binding of the drug. The nanoparticles in which MTX was 
bound via a covalent bond to HSA, γ-Fe2O3∼HSA-MTX, 
showed a slightly lower cell-kill efficacy relative to that of 
the free MTX, likely caused by the uptake difference as the 
bulkier γ-Fe2O3∼HSA-MTX nanoparticles may not be taken 
up as easily as the free MTX at the same concentration, or 
by the fact that the MTX may need to be cleaved from the 
nanoparticles before it shows the toxicity. This is in agree-
ment with the literature,12,14 suggesting it may be a good 
candidate for the delivery of MTX by CED. In one of these 
studies,14 MTX-conjugated nanoparticles were also shown to 
have targeting specificity for the same tumor cell line (9L rat 
glioma) used in our study, over a healthy cell line (Cultured 
Pulmonary Artery Endothelial).
The goal of the in vivo study was to assess the distribu-
tion efficacy of the different nanoparticles, to test for toxic-
ity, and to evaluate the clearance time from the tissue. The 
distribution efficacy of all the coated particles was found to 
be efficient and significantly higher than that of the naked 
particles. The PEG coating seemed to provide a similar dis-
tribution efficacy to that of the HSA coating since there was 
no significant difference between the distribution volumes 
of the γ-Fe2O3∼PEG and the γ-Fe2O3∼HSA nanoparticles. 
On the other hand, the γ-Fe2O3∼HSA-MTX had slightly 
lower distribution volumes. There was no significant dif-
ference between those and the distribution volumes of the 
HSA particles without the MTX, but there was a significant 
difference when comparing the γ-Fe2O3∼PEG with the 
γ-Fe2O3∼HSA-MTX, suggesting that the MTX binding may 
somewhat decrease the distribution efficacy of the particles. 
However, the distribution volume of the γ-Fe2O3∼HSA-MTX   
particles was more than twice that of the naked particles, 
implying that these are good candidates for CED treatment. 
The clearance time of the latter seems to be somewhat slower 
than that of the other coated particles, resulting in very similar 
distributions 19 days post treatment.
In this study, we have demonstrated the feasibility 
of binding an anti-cancer agent, MTX, to biodegradable 
maghemite nanoparticles, while preserving the penetration 
of the particles into the cells, and the efficacy of the drug 
against cancer cells. In addition, we have shown that the 
chosen formulation provides efficient distributions of the 
particles in rat brains, depicted by MRI in real time, with no 
apparent toxicity, and that the clearance time of the particles 
is long, enabling slow drug release.
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